Lupin reported a 68% YoY EBITDA growth to INR 2,171 crores in Q4 FY26, marking its 15th consecutive quarter of growth.
US sales reached a record USD 1.318 billion for FY26, driven by new complex product launches like generic Risperdal Consta® and Tolvaptan.
The company provided FY27 guidance for high-single digit revenue growth and EBITDA margins around 25%, factoring in new competition.
Lupin ended FY26 with a strong net cash position of INR 4,636 crores and is actively seeking strategic acquisitions in specialty segments.